Aspects of immune dysfunction in end-stage renal disease

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 5, 2008, Pages 1526-1533

  Kato, Sawako ^a,b   Chmielewski, Michal ^a,c   Honda, Hirokazu ^d   Pecoits Filho, Roberto ^e   Matsuo, Seiichi ^b   Yuzawa, Yukio ^b   Tranaeus, Anders ^a   Stenvinkel, Peter ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMMUNICABLE DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; KIDNEY FAILURE, CHRONIC; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 53749090099     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00950208     Document Type: Review

References (66)

1. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418, 2004
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
3. Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58: 1758-1764, 2000
4. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 20: 197-216, 2002
5. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 343: 338-344, 2000
6. Pasare C, Medzhitov R: Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 6: 1382-1387, 2004
7. Delves PJ, Roitt IM: The immune system: first of two parts. N Engl J Med 343: 37-49, 2000
8. Slavik JM, Hutchcroft JE, Bierer BE: CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 19: 1-24, 1999
9. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997
10. Zuany-Amorim C, Hastewell J, Walker C: Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 1: 797-807, 2002
11. Shahin RD, Engberg I, Hagberg L, Svanborg Eden C: Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J Immunol 138: 3475-3480, 1987
12. Schroder NW, Schumann RR: Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5: 156-164, 2005
13. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347: 185-192, 2002
14. Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5: 975-979, 2004
15. Czyzyk J: The role of Toll-like receptors in the pathogenesis of renal disease. Semin Nephrol 26: 167-172, 2006
16. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP: The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 41[Suppl]: S408-S415, 2005
17. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S: A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522-1526, 2004
18. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
19. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67: 1216-1233, 2005
20. Satomura A, Endo M, Ohi H, Sudo S, Ohsawa I, Fujita T, Matsushita M, Fujita T: Significant elevations in serum mannose-binding lectin levels in patients with chronic renal failure. Nephron 92: 702-704, 2002
21. Berger SP, Roos A, Mallat MJ, Schaapherder AF, Doxiadis II, van Kooten C, Dekker FW, Daha MR, de Fijter JW: Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 18: 2416-2422, 2007
22. Satomura A, Endo M, Fujita T, Ohi H. Ohsawa I, Fuke Y, Matsumoto K, Sudo S, Matsushita M, Fujita T: Serum mannose-binding lectin levels in maintenance hemodialysis patients: impact on all-cause mortality. Nephron Clin Pract 102: 93-99, 2006
23. Ando M, Lundkvist I, Bergstrom J, Lindholm B: Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int 49: 773-780, 1996
24. Ando M, Gafvels M, Bergstrom J, Lindholm B, Lundkvist I: Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int 51: 785-792, 1997
25. Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B: Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs 29: 608-614, 2005
26. Ando M, Shibuya A, Yasuda M, Azuma N, Tsuchiya K, Akiba T, Nitta K: Impairment of innate cellular response to in vitro stimuli in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 20: 2497-2503, 2005
27. Lim WH, Kireta S, Leedham E, Russ GR, Coates PT: Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 72: 1138-1148, 2007
28. Verkade MA, van Druningen CJ, Vaessen LM, Hesselink DA, Weimar W, Betjes MG: Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 22: 128-138, 2007
29. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E: The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant 18: 2067-2073, 2003
30. Glorieux G, Vanholder R, Lameire N: Uraemic retention and apoptosis: what is the balance for the inflammatory status in uraemia? Eur J Clin Invest 33: 631-634, 2003
31. Cohen G, Rudnicki M, Deicher R, Horl WH: Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest 33: 669-676, 2003
32. Wann JG, Hsu YH, Yang CC, Lin CS, Tai DW, Chen JS, Hsiao CW, Chen CF: Neutrophils in acidotic haemodialysed patients have lower intracellular pH and inflamed state. Nephrol Dial Transplant 22: 2613-2622, 2007
33. Cohen G, Rudnicki M, Walter F, Niwa T, Horl WH: Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 12: 1264-1271, 2001
34. Galle J, Schneider R, Heinloth A, Warmer C, Galle PR, Conzelmann E, Dimmeler S, Heermeier K: Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 55: 1450-1461, 1999
35. Kettritz R, Falk RJ, Jennette JC, Gaido ML: Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis. J Am Soc Nephrol 8: 1091-1100, 1997
36. Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ: Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 10: 93-100, 1999
37. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B: Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16: 2431-2438, 2005
38. Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. Clin Nephrol 68: 1-9, 2007
39. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 80: 103-108, 2002
40. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41: 1212-1218, 2003
41. Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: the interleukin hypothesis. Blood Purif 11: 13-18, 1983
42. Opatrny K Jr: Clinical importance of biocompatibility and its effect on haemodialysis treatment. Nephrol Dial Transplant 18[Suppl]: S41-S44, 2003
43. Hernandez MR, Galan AM, Cases A, Lopez-Pedret J, Pereira A, Tonda R, Bozzo J, Escolar G, Ordinas A: Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation. Am J Nephrol 24: 235-241, 2004
44. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 20: 440-451, 2007
45. Meuer SC, Hauer M, Kurz P, Meyer zum Buschenfelde KH, Kohler H: Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 80: 743-749, 1987
46. Stachowski J, Pollok M, Burrichter H, Spithaler C, Baldamus CA: Signalling via the TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. Nephron 64: 369-375, 1993
47. Sester U, Sester M, Hauk M, Kaul H, Kohler H, Girndt M: T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 15: 1217-1223, 2000
48. Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC, de Francisco AL, Lopez-Hoyos M, Arias M: B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bc1-2. Nephrol Dial Transplant 15: 502-510, 2000
49. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73: 391-398, 2008
50. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J: Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 53: 773-782, 1998
51. Wolfson M, Strong CJ, Minturn D, Gray DK, Kopple JD: Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 39: 547-555, 1984
52. Reddan DN, Klassen PS, Szczech LA, Coladonato, JA, O'Shea S, Owen WF Jr, Lowrie EG: White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 18: 1167-1173, 2003
53. Girndt M, Sester M, Sester U, Kaul H, Kohler H: Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 59: 1382-1389, 2001
54. Ando M, Shibuya A, Tsuchiya K, Akiba T, Nitta K: Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 70: 358-362, 2006
55. Kuroki Y, Tsuchida K, Go I, Aoyama M, Naganuma T, Takemoto Y, Nakatani T: A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients. Int J Mol Med 19: 783-790, 2007
56. Kato S, Yuzawa Y, Tsuboi N, Maruyama S, Morita Y, Matsuguchi T, Matsuo S: Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of toll-like receptor 4. J Am Soc Nephrol 15: 1289-1299, 2004
57. Chowdhury P, Sacks SH, Sheerin NS: Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol 145: 346-356, 2006
58. Patole PS, Schubert S, Hildinger K, Khandoga S, Khandoga A, Segerer S, Henger A, Kretzler M, Werner M, Krombach F, Schlondorff D, Anders HJ: Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis. Kidney Int 68: 2582-2587, 2005
59. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002
60. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination, N Engl J Med 351: 2611-2618, 2004
61. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J: Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103: 1064-1070, 2001
62. Carrero JJ, Yilmaz; MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 26: 291-299, 2008
63. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
64. Stenvinkel P, Heimburger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39: 274-282, 2002
65. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684-1688, 2002
66. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19: 53-61, 2001